Research and Markets: OpportunityAnalyzer: Genital Herpes - Opportunity Analysis and Forecasts to 2023

Research and Markets (http://www.researchandmarkets.com/research/3b8qhw/opportunityanalyze) has announced the addition of the "OpportunityAnalyzer: Genital Herpes - Opportunity Analysis and Forecasts to 2023" report to their offering.

There is currently no effective preventative vaccine or cure for GH, and the treatment landscape is dominated by generic nucleoside analogues. Despite the effectiveness of these drugs in managing the symptoms in the majority of patients, the lack of treatment alternatives and the shortcomings of the current treatments have stimulated investments in new treatment options for this vast patient population.

For the purposes of this report, the GH market includes sales of GH-specific medication in patients 18 years and older. Report expects the market to experience moderate growth that is primarily driven by the uptake of novel therapies - led by Agenus's HerpV and Genocea's GEN-003 - in the US and 5EU (France, Germany, Italy, Spain and UK).

Key Findings

- GlobalData projects the GH market in the US, 5EU and Japan to grow from approximately $490m in 2013 to $668m in 2023, at a compound annual growth rate (CAGR) of 3.1%. This growth across the 7MM will primarily be driven by the launch of pipeline agents, especially the therapeutic vaccines in the US and 5EU, while continued generic erosion across the 7MM, particularly in the 5EU and Japan, is expected to curtail market growth over the forecast period.

- While pipeline agents have the potential to address some of the unmet needs in the GH treatment, available data do not demonstrate that they will be able to fully address these issues, according to interviewed KOLs.

- GlobalData anticipates that opportunities centered on the development of therapeutic and/or prophylactic vaccines, as well as antivirals with novel MOAs, will exist for current and future players in the GH marketplace for the duration of the forecast period.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Treatment Options

6 Unmet Needs Assessment and Opportunity Analysis

7 Research and Development Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

Companies Mentioned

• GlaxoSmithKline
• Novartis
• Asahi Kasei Pharma
• Maruho
• Agenus
• Genocea
• Vical
• Sanofi Pasteur
• Admendus
• Chimerix
• Immune Design
• AiCuris

For more information visit http://www.researchandmarkets.com/research/3b8qhw/opportunityanalyze

View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005217/en/